Lunit completed the acquisition of Volpara Health Technologies for $193m.

Lunit, a medical software company, completed the acquisition of Volpara Health Technologies, a health technology software for breast cancer, for $193m. "We are thrilled to welcome Volpara into the Lunit family. Today, we take a monumental step towards revolutionizing our approach to cancer care. By combining our strengths, we are creating a formidable alliance in the industry, particularly in the US market. This merger enables us to develop and deliver innovative, life-saving solutions that meet critical needs in cancer diagnostics. While our initial focus remains on breast cancer, both Lunit and Volpara are committed to broadening our offerings to address a wider range of cancers and medical conditions. Together, we will enhance our technological capabilities and strengthen our mission to lead the global fight against cancer," Brandon Suh, Lunit CEO.